The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Distinct biomarkers as prognostic in chronic lymphocytic leukemia patients treated with alvocidib and lenalidomide as single agents or combination regimens thereof.
William E. Pierceall
Employment or Leadership Position - Eutropics Pharmaceuticals
Kami J. Maddocks
No relevant relationships to disclose
Ellen N Wei
No relevant relationships to disclose
Christine Chen
No relevant relationships to disclose
Steven Warner
Employment or Leadership Position - Tolero Pharmaceuticals
Stock Ownership - Tolero Pharmaceuticals
Camille Doykan
Employment or Leadership Position - Eutropics Pharmaceuticals
Ryan Lena
Employment or Leadership Position - Eutropics Pharmaceuticals
Noel Blake
Employment or Leadership Position - Eutropics Pharmaceuticals
Michael H. Cardone
Employment or Leadership Position - Eutropics Pharmaceuticals
Stock Ownership - Eutropics Pharmaceuticals
Leslie A. Andritsos
No relevant relationships to disclose
Michael R. Grever
No relevant relationships to disclose
John C. Byrd
No relevant relationships to disclose
Suzanne Trudel
No relevant relationships to disclose
Amy J. Johnson
No relevant relationships to disclose